S&P 500   4,267.52
DOW   33,665.02
QQQ   348.82
Stock market today: Asian shares slip following technology selloff on Wall Street
This Company Is Solving A Multi-Billion Dollar Problem! (Ad)
Tesla: How and Why It Gets To $300
Don't Overlook Hidden Gem Kinsale As Rallies To New Highs
The Stock That's Brining Lithium Back To America! (Ad)
AI-powered IoT Automation is Driving Samsara To New Highs
What is a Growth Stock Mutual Fund?
Laser breakthrough could send stock soaring 2,467% (Ad)
Persistent inflation, higher interest rates will weigh on global economy, OECD predicts
Sprinklr Gets Targets Raised By Analysts, Here's Why
S&P 500   4,267.52
DOW   33,665.02
QQQ   348.82
Stock market today: Asian shares slip following technology selloff on Wall Street
This Company Is Solving A Multi-Billion Dollar Problem! (Ad)
Tesla: How and Why It Gets To $300
Don't Overlook Hidden Gem Kinsale As Rallies To New Highs
The Stock That's Brining Lithium Back To America! (Ad)
AI-powered IoT Automation is Driving Samsara To New Highs
What is a Growth Stock Mutual Fund?
Laser breakthrough could send stock soaring 2,467% (Ad)
Persistent inflation, higher interest rates will weigh on global economy, OECD predicts
Sprinklr Gets Targets Raised By Analysts, Here's Why
S&P 500   4,267.52
DOW   33,665.02
QQQ   348.82
Stock market today: Asian shares slip following technology selloff on Wall Street
This Company Is Solving A Multi-Billion Dollar Problem! (Ad)
Tesla: How and Why It Gets To $300
Don't Overlook Hidden Gem Kinsale As Rallies To New Highs
The Stock That's Brining Lithium Back To America! (Ad)
AI-powered IoT Automation is Driving Samsara To New Highs
What is a Growth Stock Mutual Fund?
Laser breakthrough could send stock soaring 2,467% (Ad)
Persistent inflation, higher interest rates will weigh on global economy, OECD predicts
Sprinklr Gets Targets Raised By Analysts, Here's Why
S&P 500   4,267.52
DOW   33,665.02
QQQ   348.82
Stock market today: Asian shares slip following technology selloff on Wall Street
This Company Is Solving A Multi-Billion Dollar Problem! (Ad)
Tesla: How and Why It Gets To $300
Don't Overlook Hidden Gem Kinsale As Rallies To New Highs
The Stock That's Brining Lithium Back To America! (Ad)
AI-powered IoT Automation is Driving Samsara To New Highs
What is a Growth Stock Mutual Fund?
Laser breakthrough could send stock soaring 2,467% (Ad)
Persistent inflation, higher interest rates will weigh on global economy, OECD predicts
Sprinklr Gets Targets Raised By Analysts, Here's Why
NASDAQ:SPRB

Spruce Biosciences (SPRB) Stock Forecast, Price & News

$2.36
+0.02 (+0.85%)
(As of 06/7/2023 ET)
Compare
Today's Range
$2.30
▼
$2.41
50-Day Range
$1.92
▼
$2.60
52-Week Range
$0.95
▼
$3.57
Volume
394,866 shs
Average Volume
970,164 shs
Market Capitalization
$93.81 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$7.60
ProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesSEC FilingsShort InterestSocial Media

Spruce Biosciences MarketRank™ Forecast

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
222.0% Upside
$7.60 Price Target
Short Interest
Healthy
2.89% of Shares Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
N/A
Insider Trading
N/A
Proj. Earnings Growth
N/A

Overall MarketRank™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.94 out of 5 stars

Medical Sector

586th out of 981 stocks

Pharmaceutical Preparations Industry

271st out of 462 stocks

See Top Rated MarketRank™ Stocks Here

SPRB stock logo

About Spruce Biosciences (NASDAQ:SPRB) Stock

Spruce Biosciences, Inc., a biopharmaceutical company, focuses on developing and commercializing novel therapies for rare endocrine disorders. The company engages in developing tildacerfont, a non-steroidal therapy to enhance disease control and reduce steroid burden for adult patients suffering from congenital adrenal hyperplasia (CAH), which is in Phase 2b clinical trial; and to evaluate glucocorticoid reduction and clinical consequences in adult patients with classic CAH that is Phase 2b clinical trial. It is also developing tildacerfont for the treatment of pediatric classic congenital adrenal hyperplasia in children that is in Phase 2 clinical trial; and for females with polycystic ovary syndrome, which is in Phase 2 clinical trial. The company has a license agreement with Eli Lilly and Company to research, develop, and commercialize compounds for various pharmaceutical uses. Spruce Biosciences, Inc. was incorporated in 2014 and is headquartered in Daly City, California.

Receive SPRB Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Spruce Biosciences and its competitors with MarketBeat's FREE daily newsletter.

SPRB Stock News Headlines

May 25, 2023 | finance.yahoo.com
Spruce Biosciences Appoints Percival Barretto-Ko to Board of Directors
May 24, 2023 | finance.yahoo.com
Spruce Biosciences to Participate in the Jefferies Healthcare Conference
June 8, 2023 | Behind the Markets (Ad)
"Unknown laser company making HUGE profit from Russia-Ukraine War"
On February 24th, Russia invaded Ukraine. This caused major stock losses and soaring gas prices. But it also created a HUGE opportunity for savvy investors. There's an unknown laser company that's been profiting greatly from this war... ...and from another major conflict happening 3,000 miles away. Learn more here >>>
May 23, 2023 | msn.com
Oppenheimer Reiterates Spruce Biosciences (SPRB) Outperform Recommendation
May 22, 2023 | finance.yahoo.com
Spruce Biosciences Honored at CARES Foundation 15th Annual Everyone CARES Gala
May 17, 2023 | msn.com
RBC Capital Reiterates Spruce Biosciences (SPRB) Outperform Recommendation
May 16, 2023 | msn.com
Credit Suisse Reiterates Spruce Biosciences (SPRB) Outperform Recommendation
May 16, 2023 | msn.com
JMP Securities Reiterates Spruce Biosciences (SPRB) Market Outperform Recommendation
June 8, 2023 | Behind the Markets (Ad)
"Unknown laser company making HUGE profit from Russia-Ukraine War"
On February 24th, Russia invaded Ukraine. This caused major stock losses and soaring gas prices. But it also created a HUGE opportunity for savvy investors. There's an unknown laser company that's been profiting greatly from this war... ...and from another major conflict happening 3,000 miles away. Learn more here >>>
May 16, 2023 | markets.businessinsider.com
Analyst Expectations for Spruce Biosciences's Future
May 16, 2023 | finance.yahoo.com
Investors in Spruce Biosciences (NASDAQ:SPRB) have seen decent returns of 63% over the past year
May 16, 2023 | markets.businessinsider.com
Spruce Biosciences (SPRB) Gets a Buy from JMP Securities
May 15, 2023 | finance.yahoo.com
Spruce Biosciences Reports First Quarter 2023 Financial Results and Provides Corporate Updates
May 4, 2023 | finance.yahoo.com
Spruce Biosciences to Present Findings on Retrospective Analysis of Completion Rates for CAH Studies at Pediatric Endocrine Society 2023 Annual Meeting
April 11, 2023 | americanbankingnews.com
Cocrystal Pharma (NASDAQ:COCP) versus Spruce Biosciences (NASDAQ:SPRB) Critical Survey
April 2, 2023 | americanbankingnews.com
Equities Analysts Offer Predictions for Spruce Biosciences, Inc.'s Q1 2023 Earnings (NASDAQ:SPRB)
April 1, 2023 | americanbankingnews.com
Spruce Biosciences, Inc. Forecasted to Post Q4 2023 Earnings of ($0.36) Per Share (NASDAQ:SPRB)
March 31, 2023 | finance.yahoo.com
Spruce Biosciences, Inc. (SPRB) Upgraded to Buy: Here's What You Should Know
March 24, 2023 | americanbankingnews.com
Spruce Biosciences (NASDAQ:SPRB) Price Target Lowered to $10.00 at HC Wainwright
March 23, 2023 | markets.businessinsider.com
4 Analysts Have This to Say About Spruce Biosciences
March 22, 2023 | americanbankingnews.com
Q1 2023 EPS Estimates for Spruce Biosciences, Inc. Raised by Analyst (NASDAQ:SPRB)
March 21, 2023 | americanbankingnews.com
Spruce Biosciences (NASDAQ:SPRB) Stock Rating Reaffirmed by Credit Suisse Group
March 18, 2023 | markets.businessinsider.com
Spruce Biosciences (SPRB) Receives a Buy from Credit Suisse
March 16, 2023 | finance.yahoo.com
Spruce Biosciences Reports Full Year 2022 Financial Results and Provides Corporate Updates
March 1, 2023 | finance.yahoo.com
Spruce Biosciences to Participate in the Oppenheimer 33rd Annual Healthcare Conference
February 23, 2023 | finance.yahoo.com
2 “Strong Buy” Penny Stocks With Multibagger Potential
February 13, 2023 | markets.businessinsider.com
Analysts Offer Insights on Healthcare Companies: Petiq (PETQ) and Spruce Biosciences (SPRB)
See More Headlines

SPRB Price History

SPRB Company Calendar

Last Earnings
3/16/2023
Today
6/07/2023
Next Earnings (Estimated)
8/09/2023
Fiscal Year End
12/31/2023
Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:SPRB
CUSIP
N/A
CIK
1683553
Web
www.sprucebiosciences.com
Phone
415-655-4168
Fax
N/A
Employees
15
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$7.60
High Stock Price Forecast
$10.00
Low Stock Price Forecast
$4.00
Forecasted Upside/Downside
+223.4%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
5 Analysts

Profitability

EPS (Most Recent Fiscal Year)
($1.86)
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
$-46,180,000.00
Net Margins
N/A
Pretax Margin
-2,403.72%
Return on Equity
-54.88%
Return on Assets
-44.48%

Debt

Debt-to-Equity Ratio
0.03
Current Ratio
5.97
Quick Ratio
5.97

Sales & Book Value

Annual Sales
N/A
Price / Sales
N/A
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
$2.90 per share
Price / Book
0.81

Miscellaneous

Outstanding Shares
39,750,000
Free Float
36,725,000
Market Cap
$93.41 million
Optionable
Not Optionable
Beta
2.28

Key Executives

  • Mr. Michael G. Grey (Age 69)
    Exec. Chairman
    Comp: $65k
  • Mr. Samir M. Gharib CPA (Age 40)
    CPA, M.B.A., Pres & CFO
    Comp: $480k
  • Dr. Javier Szwarcberg M.D. (Age 52)
    M.P.H., CEO & Director
  • Dr. Ralph William Charlton III (Age 52)
    M.D., Chief Medical Officer
  • Dr. Libbie Mansell M.B.A.
    Ph.D., Chief Regulatory & Quality Officer
  • Ms. P. J. Ramtin
    Sr. VP of Bus. Operations

Key Competitors

View All Competitors

Institutional Ownership

View All Institutional Transactions













SPRB Stock - Frequently Asked Questions

Should I buy or sell Spruce Biosciences stock right now?

5 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Spruce Biosciences in the last twelve months. There are currently 5 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" SPRB shares.
View SPRB analyst ratings or view top-rated stocks.

What is Spruce Biosciences' stock price forecast for 2023?

5 equities research analysts have issued 12 month price targets for Spruce Biosciences' stock. Their SPRB share price forecasts range from $4.00 to $10.00. On average, they expect the company's stock price to reach $7.60 in the next year. This suggests a possible upside of 223.4% from the stock's current price.
View analysts price targets for SPRB or view top-rated stocks among Wall Street analysts.

How have SPRB shares performed in 2023?

Spruce Biosciences' stock was trading at $1.0974 at the start of the year. Since then, SPRB stock has increased by 114.1% and is now trading at $2.35.
View the best growth stocks for 2023 here.

When is Spruce Biosciences' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Wednesday, August 9th 2023.
View our SPRB earnings forecast.

How were Spruce Biosciences' earnings last quarter?

Spruce Biosciences, Inc. (NASDAQ:SPRB) posted its earnings results on Thursday, March, 16th. The company reported ($0.47) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.55) by $0.08.

When did Spruce Biosciences IPO?

(SPRB) raised $75 million in an initial public offering on Friday, October 9th 2020. The company issued 5,000,000 shares at a price of $14.00-$16.00 per share. Cowen, SVB Leerink, Credit Suisse and RBC Capital Markets served as the underwriters for the IPO.

What is Spruce Biosciences' stock symbol?

Spruce Biosciences trades on the NASDAQ under the ticker symbol "SPRB."

Who are Spruce Biosciences' major shareholders?

Spruce Biosciences' stock is owned by a number of institutional and retail investors. Top institutional shareholders include Armistice Capital LLC (9.88%), RiverVest Venture Management LLC (7.39%), Carlyle Group Inc. (7.29%), AIGH Capital Management LLC (2.78%), Alyeska Investment Group L.P. (2.52%) and CVI Holdings LLC (1.19%). Insiders that own company stock include Bali Muralidhar, Camilla V Simpson, Holdings A/S Novo and Venture Fund Iii L Rivervest.
View institutional ownership trends.

How do I buy shares of Spruce Biosciences?

Shares of SPRB stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Spruce Biosciences' stock price today?

One share of SPRB stock can currently be purchased for approximately $2.35.

How much money does Spruce Biosciences make?

Spruce Biosciences (NASDAQ:SPRB) has a market capitalization of $93.41 million. The company earns $-46,180,000.00 in net income (profit) each year or ($1.86) on an earnings per share basis.

How can I contact Spruce Biosciences?

The official website for the company is www.sprucebiosciences.com. The company can be reached via phone at 415-655-4168 or via email at investors@sprucebiosciences.com.

This page (NASDAQ:SPRB) was last updated on 6/8/2023 by MarketBeat.com Staff

My Account -